Navigation Links
Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
Date:5/1/2008

MOUNTAIN VIEW, Calif., May 1 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present at the 161st American Psychiatric Association annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of acute agitation in schizophrenic patients. The poster presentation, "Inhaled Loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients" (Presentation NR5-032), will be available for viewing at the meeting at the Washington Convention Center in Washington, D.C. on Tuesday, May 6, 2008 from 3:00 to 5:00 p.m. Eastern Time.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Prod
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... solutions for cardiovascular applications, today announced that they have entered ... will commence a tender offer to acquire all of the ... share, or a total equity purchase price of USD 1 ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... The AXA Research Fund closed out its first year ... than Euro 13 million to various European research institutions.The purpose ... of major risks in the world by supporting cutting edge ... Euro 100 million over five years, making it a major ...
... Research features from Mayo ClinicROCHESTER, Minn., March 23 ... of Discovery,s Edge, Mayo Clinic,s research magazine. You ... often as you wish. Reprinting is allowed with ... as your editorial policies permit: Visit http://discoverysedge.mayo.edu ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... with the healthcare sector have benefited the Massage ... Given the discretionary characteristics of industry products, the anticipated ... the five-year period has provided consumers with the means ... adults that have received a massage in a given ...
(Date:12/20/2014)... (HealthDay News) -- The holidays can be anything but ... fresh trees, scented candles and other allergy triggers. ... that have been packed away in dank basements or ... asthma patients," Dr. Rachna Shah, an affiliate faculty member ... in Loyola news release. Shah, who is also ...
(Date:12/20/2014)... 20, 2014 As Risperdal lawsuits ... in U.S. courts, Bernstein Liebhard LLP notes the ... children treated with the medication may experience elevated ... development and lactation. The study, which appears in ... adolescents who began treatment with risperidone, an antipsychotic ...
(Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
(Date:12/20/2014)... Today, Balfleet.com, one of the most ... offering 50%-70% off on its Mother of the ... mother of the bride dresses from Balfleet.com feature gorgeous ... accessible and takes pride in providing high quality dresses ... offering great discounts on our mother of the bride ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2
... ... addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, ... ... InVitria today announced the launch of Optiferrin , a high performance, well-defined and ...
... ... offers breaking news surrounding the influenza A (H1N1) virus. The latest developments on ... ... since the outbreak, leading medical newspapers, Infectious Disease News and Infectious Diseases in Children ...
... , , , Hoffa Denounces ... WASHINGTON, Sept. 16 Teamsters General President Jim Hoffa today said the ... plans worth more than $8,000 is unfair and unnecessary. , ... would also levy the 35 percent tax for family plans worth $21,000. ...
... , , , ... Wisconsin today announced the launch of an H1N1 influenza prevention campaign ... on the importance of practicing healthy habits this cold and flu ... (K-12) about how to prevent the spread of viruses--including H1N1--as well ...
... , , MINNEAPOLIS, Sept. ... announced the first ever meeting of thought leading spine surgeons to ... SI Joint pathology, a frequent cause of low back pain. ... included Steven Garfin (former president of NASS, Chief of Orthopedics at ...
... , BARCELONA, Spain, September ... be avoided in African infants using a safe, ... malaria in Infants (IPTi),with the medicine sulphadoxine-pyrimethamine (SP), ... Results of a,meta-analysis examining six clinical trials in ...
Cached Medicine News:Health News:InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 2Health News:Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A (H1N1) virus: 2Health News:Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A (H1N1) virus: 3Health News:Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 2Health News:Children's Hospital of Wisconsin Launches H1N1 Prevention Campaign Geared Toward Children 2Health News:Children's Hospital of Wisconsin Launches H1N1 Prevention Campaign Geared Toward Children 3Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 2Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 3Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 4Health News:Malaria Control Method Could Prevent 6 Million New Infant Cases 2
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source....
The IVR-Optical Tracking system is engineered for easy calibration. This procedure can be done within five minutes by trained personnel, and is the only calibration required....
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)...
Penfield Dissector #2...
Medicine Products: